US 12,455,286 B2
Cytometric assays
Ilan Volovitz, Tel Aviv (IL); Merav Lustgarten, Rehovot (IL); Zvi Ram, Ramat Gan (IL); Netanel Yakov Shapira, Efrat (IL); Idan Ben Horin, Ra′anana (IL); and Gil Diamant, Tel Aviv (IL)
Assigned to The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Tel Aviv (IL)
Filed by The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Tel Aviv (IL)
Filed on Oct. 24, 2022, as Appl. No. 17/971,720.
Application 17/971,720 is a continuation of application No. 15/780,385, granted, now 11,480,571, previously published as PCT/IL2016/051284, filed on Nov. 30, 2016.
Claims priority of provisional application 62/261,336, filed on Dec. 1, 2015.
Prior Publication US 2023/0065632 A1, Mar. 2, 2023
Int. Cl. G01N 33/533 (2006.01); G01N 33/569 (2006.01)
CPC G01N 33/56972 (2013.01) [G01N 33/533 (2013.01); G01N 33/56977 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01); G01N 2333/70596 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A kit for identifying innate immune cell populations in a human tissue sample, comprising a distinguishably distinct fluorescent viability dye and distinguishably distinct fluorophore-labeled antibodies directed to human CD45, CD11b, CD14, HLA-DR, and CD16 and wherein said distinguishably distinct fluorophore-labeled antibody directed to human CD45 comprises a fluorophore with a staining index of at least 200; and optionally a distinguishably distinct fluorophore-labeled antibody directed to CD33.